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Microabstract 
We found no difference in prostate cancer death between men with favourable-risk localised prostate 
cancer managed with immediate radical prostatectomy or on active surveillance following 10 years. 
Additionally, we found difference in use of salvage radiotherapy and hormonal therapy between the 
strategies.  
Short summary 
Localised prostate cancer with favourable-risk characteristics often progresses slowly with a 
subsequent low risk of dying from prostate cancer and a high risk of dying from other causes.  
Although curative options are available the management of men with favourable-risk characteristics 
remains controversial. Active surveillance has been introduced as a tailored management for these 
men in order to reduce curative overtreatment without compromising cancer-specific survival.  
In the current study we included 647 men who were managed on active surveillance and 647 men 
who underwent primary radical prostatectomy identified following propensity score matching and 
who were followed for a medium of 8.6 years. The 10-year prostate cancer mortality was similar and 
very low for men managed on active surveillance (0.4%) and who underwent primary radical 
prostatectomy (0.5%). In addition only few men required subsequent prostate cancer therapies or 
developed castration resistant prostate cancer with no significant difference between the treatment 
strategies. 10-year cumulative estimates for use of salvage radiotherapy were 2.7% for men on active 
surveillance and 5.4% for men who underwent radical prostatectomy. Corresponding numbers for 
definitive hormonal therapy was 6.9% (active surveillance) and 4.1% (radical prostatectomy), and for 
developing castration-resistant prostate cancer 1.7% (active surveillance) and 2.0% (radical 
prostatectomy). 
Our study supports active surveillance as a treatment strategy for men with favourable-risk localised 
prostate cancer; however, longer follow-up is needed to determine the long-term safety of an initial 
observational approach.
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Abstract 
Background: Active surveillance (AS) and radical prostatectomy (RP) are both accepted treatments 
for men with favourable-risk localised prostate cancer (PCa) – i.e. clinical tumour category 1-2b, 
Gleason Grade Group 1-2 and prostate-specific antigen <20 ng/mL. However, head-to-head studies 
comparing oncological outcomes and survival between these two treatment strategies are warranted.  
Objective: To compare use of prostate cancer treatments and PCa death in men managed on AS and 
men who underwent immediate RP. 
Design, setting, and participants: Observational study including 647 men on AS and 647 men 
treated with RP propensity score matched. 
Outcome measurements and statistical analysis: 10-year cumulative incidence of salvage 
radiotherapy, hormonal therapy, castration-resistant PCa (CRPC) and PCa death. 
Results and limitations: The 10-year curative treatment-free survival for men on AS was 61% (95% 
CI 57-65%). No differences in use of salvage radiotherapy (AS 2.7% [95% CI 1.4-4.1%] vs. RP 5.4% 
[95% CI 3.4-7.3%]), hormonal therapy (AS 6.9% [95% CI 4.4-9.4%] vs. RP 4.1% [95% CI 2.5-5.6%]), 
developing CRPC (AS 1.7% [95% CI 0.5-2.9%] vs. RP 2.0% [95% CI 0.7-3.4%]) or cumulative PCa 
mortality (AS 0.4% [95% CI 0-1.0%] vs. RP 0.5% [95% CI 0-1.5%]) were observed between the 
treatment strategies. The main limitation was the non-random allocation to treatment strategy. 
Conclusion: In this observational study on men with favourable-risk localised PCa we found similar 
PCa mortality at 10-years between men on AS and men who underwent immediate RP. Moreover, 
there were no differences in the use of PCa therapies between the groups. Our study supports active 
surveillance as a treatment strategy for men with favourable-risk localised PCa. 
Patient summary: The risk of dying from PCa was similar between men with favourable-risk localised 
prostate cancer who were managed on active surveillance (close observational strategy with the 
possibility of curative treatment) or radical prostatectomy (surgical removal of the prostate).
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INTRODUCTION 
As a consequence of increased focus on early detection of prostate cancer the incidence of prostate 
cancer has increased drastically in the last decades1. This has led to more men that are diagnosed with 
localised, low-volume disease2. Although curative options for men with localised prostate cancer are 
available the management of these men remains controversial. Prostate cancer often progresses 
slowly and men with localised prostate cancer have a high risk of dying from causes other than 
prostate cancer3. This is especially the case in men with favourable-risk characteristics, i.e. clinical 
tumour category (cT) 1-2b, prostate-specific antigen (PSA) less than 20 ng/mL and Gleason score less 
than or equal to 7 (3+4). Still, some men with favourable-risk localised prostate cancer will die from 
the disease3.  
Active surveillance has been introduced as a tailored management for selected men with localised 
prostate cancer in order to reduce curative overtreatment by identifying men who will likely benefit 
from definitive therapy, while men with true favourable-risk prostate cancer are spared curative 
interventions and its adverse effects4,5. The first randomized controlled trial comparing an initially 
observational strategy to immediate curative interventions (either radical prostatectomy or 
radiotherapy) in men with localised prostate cancer, found no survival difference between the 
treatment strategies following 10 years of observation6. 
Well conducted observational studies are important additions to clinical trials to evaluate the outcome 
of managements in a real-world setting7. The objective of this study was to compare oncological 
outcomes in two Danish cohorts of men diagnosed with localised prostate cancer managed either on 
active surveillance or having radical prostatectomy as their primary treatment. 
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MATRIAL AND METHODS 
This study is based on two cohorts of Danish men with prostate cancer managed on either active 
surveillance in 2002-2012 or radical prostatectomy in 1995-2011, both cohorts have been described 
previously8,9. Available diagnostic characteristics in all men included age, type, date and region of 
primary treatment, cT, PSA and Gleason score, which in this study is reported according to the five-tier 
Gleason Grade Group (GGG)10. No uniform surveillance strategy was adhered to as men were managed 
at 10 different urological departments8. However, all centers assessed men with a combination of 
surveillance biopsies, regular PSA measurement and digital rectal examinations. MRi was not part of 
the diagnostic work-up and for the vast majority not used for surveillance. Following radical prostatectomy 
men were usually assessed in the out-patient clinic with PSA measurements after 3, 6, 12, 18 and 24 
months and annually henceforth either in the out-patient clinic or at their General Practitioner9. PSA 
recurrence was defined as a confirmed PSA of 0.2 or higher. 
In order to identify two comparable cohorts we performed a propensity score matching for treatment 
strategy. We excluded men treated prior to 2002, men with cT2c-4 and/or GGG 3-5 and/or PSA above 
20 ng/mL, Figure 1. In total, 908 men on active surveillance and 3.772 men treated with radical 
prostatectomy were included for matching. Patient chart review was performed during March-May 
2018 in men who following propensity score matching were included in this study. The following was 
recorded: date and type of all subsequent prostate cancer treatments, date of fulfilling the EAU’s 
definition of castration-resistant prostate cancer11 and survival status. Cause of death was defined as 
prostate cancer or other. Follow-up was calculated from the date of treatment to event of interest or 
censured at last known date alive. 
We risk stratified men into low-risk prostate cancer (cT1-2a and GGG 1 and PSA less than 10 ng/mL) 
or intermediate-risk prostate cancer (cT2b and/or GGG 2 and/or PSA 10-20 ng/mL). 
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The study was approved by the Danish Data Protection Agency (file#2011-41-6926), the Capital 
Region of Denmark (file#2012-58-0004) and the Danish Patient Safety Authority (file#3-3013-1887 
and file#6-8011-916). 
 
Statistics 
Propensity score matching was performed with the MatchIt package for R using a caliper of 0.05 and 
included the following variables: age (continuous), diagnostic region (Capital and Zealand, Central, 
North, South), year of treatment (2002-2005, 2006-2009, 2010-2012), cT (1 vs. 2a/b), GGG (1 vs. 2) 
and PSA (continuous). Baseline characteristics between the matched cohorts were compared with Chi-
squared test and Kruskal-Wallis test. Follow-up was calculated with the reverse Kaplan-Meier method. 
Kaplan-Meier analyses were used to estimate curative treatment-free survival for men on active 
surveillance presented with 95% confidence interval (CI). Cumulative incidence of commencing 
salvage radiotherapy, definitive hormonal therapy (either antiandrogen monotherapy or castration 
therapy), castration-resistant prostate cancer and prostate cancer death was assessed with non-
prostate cancer death treated as competing event. Gray’s test was used to assess differences between 
the treatment strategies. Cause specific multivariable Cox proportional hazards regression analyses 
were performed adjusting for: age (<60, 60-64, 65-69, 70+), diagnostic region (Capital and Zealand, 
Central, North, South), year of treatment (2002-2005, 2006-2009, 2010-2012), cT (1 vs. 2a/b), GGG (1 
vs. 2) and PSA (<5, 5-<10, 10-<20). Results are presented as hazard ratios (HR) with 95% CI. All tests 
were two-sided and the significance level was set to p < 0.05. Statistical analysis was performed using 
R (R Foundation for Statistical Computing, Vienna, Austria).  
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RESULTS 
In total, 647 men from each treatment strategy were identified in the propensity score matching with 
a median follow-up of 8.6 years (95% CI 8.4-8.8 years). The cohorts were well balanced on baseline 
characteristics with no significant differences, Table 1. The largest differences were that 13% of men 
on active surveillance had GGG 2 compared to 16% of men treated with radical prostatectomy and that 
15% of men on active surveillance were younger than 60 years of age compared to 18% of men 
treated with radical prostatectomy. According to risk stratification 376 (58%) men on active 
surveillance and 371 (57%) men who underwent radical prostatectomy had low-risk prostate cancer. 
Thus, 271 (42%) men on active surveillance and 276 (43%) of men who underwent radical 
prostatectomy had intermediate-risk prostate cancer.    
The 5-year curative treatment-free survival for men on active surveillance was 68% (95% CI 64-71%) 
and at 10 years it was 61% (95% CI 57-65%). The median time on active surveillance before changing 
to curative treatment was 1.8 years, Figure 2. Overall, there were no differences in use of either 
salvage radiotherapy or hormonal therapy or in developing castration-resistant prostate cancer 
between the treatment strategies, Figure 3. At 10 years the cumulative incidence of salvage 
radiotherapy was 2.7% (95% CI 1.4-4.1%) for men primary on active surveillance compared to 5.4% 
(95% CI 3.4-7.3%) of men treated with radical prostatectomy, p = 0.46. Corresponding numbers for 
commencing definitive hormonal therapy were 6.9% (95% CI 4.4-9.4%) and 4.1% (95% CI 2.5-5.6%), 
p = 0.81, and for developing castration-resistant were 1.7% (95% CI 0.5-2.9%) and 2.0% (95% CI 0.7-
3.4%), p = 0.92. Comparable results were attained when stratified on risk category, Table 2. For men 
on active surveillance the median time to salvage radiotherapy was 3.3 years, while the median time to 
definitive hormonal therapy was 4.8 years, Figure 2. Corresponding numbers for men who underwent 
radical prostatectomy was 3.0 years and 2.1 years, respectively. 
In cause specific multivariable COX regression analyses compared to men treated with radical 
prostatectomy men on active surveillance had similar risk of commencing hormonal therapy, HR 1.56 
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(95% CI 0.92-2.65), as well as similar risk of developing castration-resistant prostate cancer, HR 1.21 
(95% CI 0.49-3.03), Table 3.  
In total, 129 men died during follow-up – including 9 prostate cancer deaths. The 10-year prostate 
cancer mortality was 0.4% (95% CI 0-1.0%) for men on active surveillance compared to 0.5% (95% CI 
0-1.5%) for men treated with radical prostatectomy, p = 0.15. The 10-year cumulative non-prostate 
cancer mortality was 9.4% (95% CI 7.2-11.7%) for men on active surveillance and 9.0% (95% CI 6.8-
11.7%) for men who underwent radical prostatectomy, p = 0.61.
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DISCUSSION 
In this observational study we observed very low prostate cancer mortality in men with favourable-
risk localised prostate cancer managed on either active surveillance or immediate radical 
prostatectomy in Denmark. Following 10 years there was no difference between the two treatment 
strategies in use of salvage radiotherapy, hormone therapy or development of castration-resistant 
prostate cancer.  
The main limitation is the non-random allocation to treatment strategy where residual confounding 
cannot be ruled out. We were unable to account for comorbidities that could have influenced 
treatment decisions; however, the overall mortality was almost identical at 10 years between the 
strategies indicating that any major differences in comorbidity were unlikely. Also, we lack diagnostic 
information on number of positive biopsy cores and maximum tumour involvement. It is therefore 
possible that the tumour burden on biopsy is larger in one cohort compared to the other – most likely 
the radical prostatectomy cohort. This is the probable reason for why men with intermediate-risk 
prostate cancer who underwent radical prostatectomy had a non-significant higher cumulative 
prostate cancer death compared to men on active surveillance. On the other hand we were able to 
perform complete follow-up including all cancer therapies utilized as well as survival status.  
In contrast to many other countries, Danish guidelines recommend antiandrogen monotherapy (i.e. 
Bicalutamide 150 mg/day) as primary hormonal therapy in men with locally advanced, non-metastatic 
prostate cancer, where curative therapy is not an option (i.e. typically men with life expectancy < 10 
years and/or significant comorbidity), and for men with biochemical recurrence after curative therapy 
without distant metastases on imaging but where distant failure is suspected (i.e. short PSA doubling 
time and/or high PSA level) or in men with rising PSA following salvage radiotherapy. Castration 
therapy is normally first initiated in men who presents or develops metastatic prostate cancer visible 
on imaging. Thus, some men on active surveillance who did not undergo curative treatment but had 
clinical progression to locally advanced stage and/or high PSA and some men with biochemical 
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recurrence following radical prostatectomy initiated antiandrogen monotherapy before reaching 
metastatic prostate cancer. Therefore we were unable to assess metastases-free survival.  
Although 10-years follow-up is too short a timeframe to conclude on the long-term safety of an active 
surveillance strategy compared to an immediate curative strategy, the prostate cancer mortality was 
less than 1% in the current study – which is in accordance with results form randomized trials in the 
PSA era6,12 and cohort studies on radical prostatectomy13,14 and active surveillance15,16. Moreover, a 
Swedish observational study including 7.608 men with localised prostate cancer who underwent 
radical prostatectomy did not find a higher risk of prostate cancer death among men who underwent 
surgery more than two years after their diagnosis17. In addition, in the current study we observed no 
differences in subsequent prostate cancer therapies administered and less than 7% required 
hormonal therapy. Still, concerns about the long-term safety of active surveillance persist. Two 
Scandinavian studies have demonstrated that the cause-specific mortality in men with localised 
prostate cancer managed on watchful waiting (i.e. curative treatment not an option) is not 
insignificant in men surviving more than 10 years18,19.  
Propensity matched studies try to resemble a randomized controlled trial using observational data; 
however, without the capacity to control for residual confounding. The results from the current study 
indicate that the active surveillance strategy can achieve similar outcomes as compared to immediate 
radical prostatectomy in men with low- and intermediate-risk PCa with 10-years follow-up. 
Prospective randomized studies with follow-up beyond 10 or may be even 20 years will be required to 
evaluate long-term results. And even in such studies results may be difficult to interpret as grading 
systems, diagnostic strategies i.e. introduction of MR guided biopsies will gradually develop and be 
integrated in management of the patients. This is clearly illustrated in a recent mortality comparison 
between men included in the active arm of SPCG-4 (the only randomized trial to show a survival 
benefit in favour of curative treatment in men with localised prostate cancer20), which found that men 
diagnosed and treated 10-20 years later than men enrolled in SPCG-4 had half the prostate cancer 
mortality compared to men in SPCG-421.  
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Active surveillance is an accepted treatment strategy in men very low- or low-risk prostate cancer, 
whereas, men with intermediate-risk prostate cancer are generally considered for curative 
interventions4,5. A report from the Sunnybrook active surveillance cohort, which until 2000 included 
men with intermediate-risk prostate cancer found a 84% 15-year metastases-free survival in men 
with PSA less than 20 ng/mL and GGG 222. The current study, where the majority of men were 
diagnosed after 2005, found no significant differences in use of hormone therapy and similar risks of 
developing castration-resistant prostate cancer. It is plausible that the changes made to the Gleason 
reporting in 200523, with the subsequent improved prognosis in men with GGG 224,25, is one of the 
reasons for the similar oncological outcomes in the current study among men with intermediate-risk 
prostate cancer managed on active surveillance and radical prostatectomy.  
 
CONCLUSION 
The prostate cancer mortality was very low in men with favourable-risk localised prostate cancer 
managed on either active surveillance or radical prostatectomy in Denmark and we found no 
difference between the two treatment strategies at 10-years. In addition only few men required 
subsequent prostate cancer therapies and again no difference was observed between the strategies. 
Our study supports active surveillance as a treatment strategy for men with favourable-risk localised 
prostate cancer; however, longer follow-up is needed to determine the long-term safety of an initial 
observational approach. 
  
Figure legends 
Figure 1 CONSORT diagram   
 
Figure 2 Number of men commencing prostate cancer treatments during following for each treatment 
strategy. The median time (t) from initiation of primary treatment (i.e. active surveillance or radical 
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prostatectomy) to commencing a given treatment is presented in years (yrs).  
 
Figure 3 Cumulative incidence of salvage radiotherapy, hormonal therapy, castration-resistant 
prostate cancer, prostate cancer death and non-prostate cancer death for men managed on active 
surveillance and men treated with radical prostatectomy.
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Table 1   Diagnostic characteristics of men with localized prostate cancer managed on active surveillance or 
radical prostatectomy.  
 Active surveillance  Radical prostatectomy   
 n = 647  n = 647   
 
n %  n %  p 
Year of treatment 
  
    0.97* 
 
2002-2005 58 (9)  59 (9)   
 
2006-2009 310 (48)  313 (48)   
 
2010-2012 279 (43)  275 (43)   
Region of Denmark       0.59* 
 Capital and Zealand 402 (62)  379 (59)   
 Central 67 (10)  77 (12)   
 North 117 (18)  128 (20)   
 Southern 61 (9)  65 (10)   
Age, year 
  
    0.26* 
 
Median (IQR) 65 (61-67)  64 (61-67)   
 
<60 96 (15)  116 (18)   
 
60-64 216 (33)  228 (35)   
 
65-69 260 (40)  240 (37)   
 
≥70 75 (12)  63 (10)   
Clinical tumor category       0.45* 
 
1 547 (85)  536 (83)   
 
2a/b 100 (15)  111 (17)   
Gleason Grade Groups       0.11* 
 
1 565 (87)  544 (84)   
 
2 82 (13)  103 (16)   
Prostate-specific antigen, ng/mL       0.78** 
 
Median (IQR) 6.8 (5.2-9.5)  6.8 (5.3-9.4)   
 
<5 136 (21)  130 (20)   
 
5-<10 378 (58)  375 (58)   
 
10-20 133 (21)  142 (22)   
* Chi-squared test **Kruskal-Wallis test 
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Table 2   Cumulative incidence estimated with competing risk analyses for 647 managed on active surveillance and 647 men managed with 
radical prostatectomy and stratified on risk category* 
 All men  Low-risk  Intermediate-risk 
 Active surveillance Radical prostatectomy  Active surveillance Radical prostatectomy  Active surveillance Radical prostatectomy 
 n = 647 n = 647  n = 376 n = 371  n = 271 n = 276 
 Estimate 95% CI Estimate 95% CI  Estimate 95% CI Estimate 95% CI  Estimate 95% CI Estimate 95% CI 
Salvage radiotherapy 
    
      
    
 10-year estimate 2.7 1.4-4.1 5.4 3.4-7.3  2.2 0.7-3.7 4.7 2.1-7.3  1.4 0.9-6.3 6.4 3.4-9.3 
Hormonal therapy 
    
      
    
 10-year estimate 6.9 4.4-9.4 4.1 2.5-5.6  5.6 2.7-8.5 2.9 1.1-4.5  9.0 4.2-13.8 5.8 3.1-8.6 
Castration-resistant prostate cancer 
    
      
    
 10-year estimate 1.7 0.5-2.9 2.0 0.7-3.4  1.1 0.3-2.1 1.5 0-3.2  3.0 0-5.9 2.7 0.7-4.8 
Prostate cancer death 
    
      
    
 10-year estimate 0.4 0-1.0 0.8 0.01-1.4  0.5 0-1.3 0.3 0-0.8  0.4 0-1.1 1.5 0.04-2.9 
Non-prostate cancer death 
    
      
    
 10-year estimate 9.4 7.2-11.7 9.0 6.8-11.2  8.5 5.7-11.3 6.7 4.2-9.3  10.7 7.0-14.4 12.0 8.1-15.8 
Abbreviations   CI confidence interval 
*Risk category definition: Low-risk: cT1-2a and GGG 1 and PSA less than 10 ng/mL; Intermediate-risk: cT2b-c and/or GGG 2-3 and/or PSA 10-20 ng/mL;  
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Table 3   Cause specific multivariable Cox regression analyses for commencing hormonal therapy or developing 
castration-resistant prostate cancer. Non-prostate cancer deaths were treated as competing events. 
 Hormonal therapy  Castration-resistant prostate cancer 
 
HR 95% CI p  HR 95% CI p 
Treatment strategy        
 
Radical prostatectomy 1 ref   1 ref  
 
Active surveillance 1.56 0.92-2.65 0.10  1.21 0.49-3.03 0.68 
Year of commencing active surveillance        
 
2002-2005 1 ref   1 ref  
 
2006-2009 0.39 0.20-0.76 0.005  0.20 0.06-0.64 0.007 
 
2010-2012 0.40 0.19-0.83 0.01  0.37 0.12-1.21 0.10 
Region        
 
Capital and Zealand 1 ref   1 ref  
 Central 1.97 1.03-3.76 0.04  0.81 0.18-3.56 0.78 
 North 0.71 0.31-1.41 0.28  0.67 0.18-2.48 0.55 
 Southern 0.66 0.25-2.04 0.52  1.44 0.39-5.28 0.58 
Age, years        
 
<60 1 ref   1 ref  
 
60-64 0.92 0.41-2.10 0.85  5.18 0.64-41.59 0.12 
 
65-69 1.28 0.58-2.83 0.54  5.83 0.73-46.94 0.10 
 
≥70 1.78 0.73-4.36 0.21  1.99 0.11-33.06 0.63 
Clinical tumor category        
 
1 1 ref   1 ref  
 
2a/b 1.87 1.06-3.31 0.03  2.63 1.02-6.74 0.04 
Gleason Grade Group        
 
1 1 ref   1 ref  
 
2 1.68 0.91-3.10 0.10  1.49 0.46-4.79 0.50 
Prostate-specific antigen, ng/mL       
 
<5 1 ref   1 ref  
 
5-<10 1.85 0.77-4.46 0.12  0.86 0.26-2.79 0.79 
 
10-20 3.21 1.28-8.02 0.01  1.22 0.33-4.48 0.76 
Abbreviations  HR hazard ratio; CI confidence interval 
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